Monday, the British-Swedish pharmaceutical industry company, AstraZeneca, revealed more positive results regarding the trial of a mixture of antibodies against coronavirus.

In addition to the antibody mixture working as a preventative shot in the non-infected, it has shown promising results in saving lives and preventing serious symptoms when given as treatment within a week of initial symptoms, according to Reuters.

The company published a statement saying that the drug known as AZD7442, which is made from a mixture of two antibodies, reduced the risk of death or severe COVID-19 by 50% in patients who were not hospitalized and those with symptoms between mild to moderate.

The statement added that the drug is currently undergoing the third phase or final clinical trials to evaluate its safety and efficacy.

Reportedly, the drug had already been submitted to the US Food and Drug Administration for emergency use as a preventive treatment.